Bringing cardiovascular cell-based therapy to clinical application: Perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting - 16/08/11

Doi : 10.1016/j.ahj.2007.02.028

E. Marc Jolicoeur, MD, MSc ^a, Christopher B. Granger, MD ^a,^⁎ , John L. Fakunding, PhD ^b, Steven C. Mockrin, PhD ^b, Steven M. Grant, MD ^c, Stephen G. Ellis, MD, FACC ^d, Richard D. Weisel, MD, FACC ^e, Margaret A. Goodell, PhD ^f
on behalf of the Working Group Members^{^g}
See Appendix for complete group membership.
^a Duke University, Durham, NC
^b NHLBI, Bethesda, MD
^c Celladon Corporation, La Jolla, CA
^d Cleveland Clinic, Cleveland, OH
^e Toronto General Hospital, Toronto, Ontario, Canada
^f Baylor College of Medicine, Houston, TX

^⁎Reprint requests: Christopher B. Granger, MD, Box 3409, Duke University, Medical Center, Durham, NC 27710.

Résumé

This article reviews the progress in cell therapy for cardiovascular disease and examines the opportunities to accelerate the process to clinical application. It draws from a meeting of the National Heart, Lung, and Blood Institute Working Group on Translation of Cell-based Therapies for Cardiovascular Disease in August 2004 to assess the status of clinical studies of cell-based therapies for cardiovascular disease, to determine the gaps in knowledge and barriers that prevent the implementation of well-designed and safe clinical studies, and to identify the areas of opportunity to apply cell-based therapies for cardiovascular disease to facilitate the clinical implementation of cell-based therapies for cardiovascular disease. We present the perspectives of experts in stem cell biology, cardiovascular physiology, cardiology, clinical research, and regulatory issues confronting the field of cell therapy for cardiovascular disease.

Le texte complet de cet article est disponible en PDF.

Plan

Export

Vol 153 - N° 5

P. 732-742 - mai 2007 Retour au numéro

Article précédent

Prediction of first coronary events with the Framingham score: A systematic review
Klaus Eichler, Milo A. Puhan, Johann Steurer, Lucas M. Bachmann

| Article suivant

The Cobalt chromium STent with Antiproliferative for Restenosis II (COSTAR II) Trial study design: Advancing the active-control evaluation of second-generation drug-eluting stents
Tracy Y. Wang, Vic Hasselblad, John L. Peterson, William Wijns, Azin Parhizgar, Dean J. Kereiakes, Mitchell W. Krucoff

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Bringing cardiovascular cell-based therapy to clinical application: Perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting - 16/08/11

Résumé

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL